Douglas Rissing
Shares of Lenz Therapeutics (LENZ) slipped for the third consecutive session on Thursday after Bank of America downgraded the eye drug developer to Neutral from Buy, citing a slower-than-expected rollout of its presbyopia therapy VIZZ.
In addition, analyst Jason Gerberry lowered